By Jens Leutloff, Senior Consultant Email [email protected] The discussion of cost containment measures in the German healthcare system does not seem to stop, and could
By Andrea Bernardini, Analyst & Akshay Kumar, Partner Email: [email protected] [email protected] On the 12th of February the Orphan Drugs Observatory and the Italian Society of
By Chloe Sheppard, Senior Analyst & Max Rex, Consultant Email: [email protected] [email protected] Cost-effectiveness analyses, as part of Health Technology Assessments (HTAs) for new therapies, appear
By Erfan Akbraian, Analyst Email: [email protected] On World Cancer Day, 4th February 2021, President Emmanuel Macron announced France’s 10-year Cancer plan1. His predecessors have rolled
By Akshay Kumar, Partner & Andrea Bernardini, Analyst Email: [email protected] [email protected] In the latest guidelines for Pricing and Reimbursement (P&R) dossier submissions, Italian Medicines Agency
By Erfan Akbraian, Analyst Email: [email protected] In recent years there have been discussions to shift to a multi-stakeholder approach and increase early communication amongst key
By Akshay Kumar, Partner & Andrea Bernardini, Analyst Email: [email protected] [email protected] Bulgaria introduced multiple reforms to their healthcare system since 2011. This included the introduction of
By Nicola Allen, Associate Director & Andrea Bernardini, Analyst Email: [email protected] or [email protected] The French Authorisation for Temporary Use (ATU) was originally established in 1994
By Ciaran Cassidy, Snr Analyst Email: [email protected] With one of the fastest-growing economies and the second largest population in the world India is a market
